Speaker Profile
Ignacio Garrido-laguna

Ignacio Garrido-laguna MD, PhD

Oncology, Haematology, Gastrointestinal Endoscopy
Salt Lake City, Utah, United States of America

Connect with the speaker?

Ignacio Garrido-Laguna, MD, Ph.D. is an Associate Professor of Oncology (tenure-track) at the University of Utah School of Medicine and a member of the Experimental Therapeutics Program at Huntsman Cancer Institute (HCI). At HCI, he sees patients with gastrointestinal cancers and patients enrolled in Phase I trials.

Garrido-Laguna’s primary research interest is pancreatic ductal adenocarcinoma (PDA). Dr.Garrido-Laguna and Dr.Kadrmas are co-PI in R21CA182977 to evaluate the role of FDG/FLT/Oxygen labeled water PET to predict response to nab-paclitaxel plus gemcitabine in patients with borderline resectable or locally advanced pancreatic cancer undergoing induction chemotherapy.

He and his team are also leading efforts to identify exceptional responders to therapy among pancreatic cancer patients enrolled in first-in-man studies in the last decade. He is PI of multiple clinical trials including novel therapies such as immunotherapies that hold promise in the treatment of this disease.

Before joining HCI, Garrido-Laguna was a clinical fellow in the Phase I program at the University of Texas MD Anderson Cancer Center. He completed his postdoctoral fellowship in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. While at Hopkins, he worked extensively in patient-derived xenografts. His research showed that stroma (tissue around the tumor that gives nutrition to cancer cells) is involved in resistance to chemotherapy in pancreatic cancer. Garrido-Laguna finished his internship and residency in medical oncology at Hospital Universitario 12 de Octubre in Madrid, Spain. Garrido-Laguna received his media
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)